Key Highlights
- Can-Fite BioPharma completed dosing for the 247 patients in its interim analysis cohort.
- The study evaluates oral Piclidenoson in moderate-to-severe plaque psoriasis.
- The trial follows a protocol agreed with U.S. and European regulators, according to Can-Fite.
- The company expects an independent committee's interim readout in Q1 2027.
Can-Fite BioPharma (NYSEAM:CANF) said on November 18 that the last patient in the group designated for an interim analysis of its Phase III psoriasis study had received the final scheduled dose. The group comprises the first 247 patients in the trial of Piclidenoson. Can-Fite expects an independent monitoring committee to read out the interim results in the first quarter of 2027.
Dosing milestone for the first 247 patients
The announcement follows Can-Fite's earlier disclosure that patient recruitment had been completed for the group whose data will be included in the interim analysis. The latest update concerns the end of study treatment for that group. The analysis is intended to assess safety and efficacy in patients with moderate-to-severe plaque psoriasis. Can-Fite said the timing of the readout follows the trial's plan for a prespecified interim assessment.
Piclidenoson is an investigational oral drug. The company is studying it as a potential treatment for psoriasis and describes it as acting on the A3 adenosine receptor. It said the drug's development program has accumulated safety data from more than 1,500 participants. That figure covers the broader development program. The first 247 patients in the current Phase III study form the group designated for the interim review.
How the Phase III trial assesses outcomes
Can-Fite described the trial as randomized, double-blind and placebo-controlled. It assigns patients to receive either oral Piclidenoson or placebo. The company said it is conducting the study under a protocol agreed with the U.S. Food and Drug Administration and the European Medicines Agency. That agreement concerns the design of the study. The drug remains investigational.
The study has two main measures of efficacy at week 16. The first tracks the proportion of patients who have at least a 75% improvement on the Psoriasis Area and Severity Index, a measure known as PASI 75. The second tracks the percentage of patients whose skin is rated clear or almost clear by a physician, corresponding to a score of zero or one on the static Physician's Global Assessment. Both measures are set points for evaluating patient outcomes in the trial.
Independent review of interim data
The Independent Data Monitoring Committee is expected to review the planned interim analysis. Can-Fite identified the first quarter of 2027 as the anticipated timing for the readout. The November update confirmed completion of dosing and did not include interim efficacy or safety results. The assessment will use data from the group of patients identified in the trial plan.
Can-Fite is a clinical-stage company with drug candidates under study for inflammatory and oncological conditions. Its November announcement addresses the Piclidenoson program and the next step in that program's Phase III study. The data under review will concern the use of the investigational medicine in patients with moderate-to-severe plaque psoriasis.
Can-Fite also listed several clinical programs for a separate candidate, Namodenoson. These include a Phase III trial in patients with hepatocellular carcinoma, a liver cancer and earlier-stage studies in other conditions. The Q1 2027 readout mentioned in the announcement applies specifically to the Piclidenoson psoriasis study.
The next scheduled trial update
Can-Fite expects the interim committee readout in early 2027. The trial has specified the timing of its efficacy assessments and the participant group for the interim review. The next announced milestone is the analysis of the data gathered for that group, following completion of dosing for those patients.






Please wait processing your request...